- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE HealthCare to Showcase Emerging PET/CT Technologies at SNMMI Conference
In addition to new advances in PET/CT imaging to facilitate precision imaging, the company will also unveil a device at the SNMMI conference that allows in-house production of commercial PET tracers.
Emphasizing precision imaging, GE HealthCare will feature a variety of emerging positron emission tomography/computed tomography (PET/CT) modalities at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNNMI) conference.
One of the showcased modalities is the Omni Legend 21 cm, a PET/CT system that reportedly offers bolstered quality for oncologic imaging, improved capability with cardiac tracers and enhanced visualization of amyloid volume associated with Alzheimer’s disease, according to GE HealthCare.
GE HealthCare is showing the Omni Legend 21 cm PET/CT system at the 2024 SNMMI conference. Currently not cleared by the FDA nor licensed in Canada, the emerging technology reportedly offers bolstered quality for oncologic imaging and enhanced visualization of amyloid volume associated with Alzheimer’s disease, according to GE HealthCare. (Image courtesy of GE HealthCare.)
GE HealthCare said other technologies debuting at SNMMI include:
• the MINItrace Magni, a device that enables cost-effective, in-house production of commercial PET tracers;
• the portable PET/CT Omni Legend Mobile, which may facilitate improved access to nuclear medicine imaging at regional or local hospital facilities; and
• the bone SPECT trained Clarify DL, which offers improved noise reduction with deep learning reconstruction.
“While there is still much work to be done, we are proud to offer a variety of technologies that can evolve with healthcare system needs and help support a patient’s entire care journey – from the systems required to create the radiotracers used to diagnose and monitor disease, to the imaging equipment used for a noninvasive look at a patient’s anatomy and treatment monitoring, to the software optimized to measure lesion size and dose,” noted Jean-Luc Procaccini, the president and chief executive officer of molecular imaging and computed tomography at GE HealthCare. “In the hands of clinicians, these tools help make the practice of precision care more accessible and aim to help improve patient outcomes globally.”
GE HealthCare noted that Clarify DL is pending 510(k) clearance from the Food and Drug Administration (FDA) and is currently not licensed for use in Canada. The company said the Omni Legend 21 cm is currently not cleared by the FDA nor licensed in Canada. The MINItrace Magni is currently in ongoing development, according to GE HealthCare.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
Study Assesses Amyloid PET/MRI Combination in Detection of Alzheimer’s Disease
July 15th 2024Emerging research revealed that a machine learning combination of amyloid beta PET and structural MRI demonstrated an 89 percent AUC in differentiating between older healthy patients and those with Alzheimer’s disease.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
Study Examines Prognostic Value of 68Ga-PSMA-11 PET/CT for Patients at High Risk of PCa
June 21st 2024Initial detection of metastatic prostate cancer via 68Ga-PSMA-11 PET/CT was significantly associated with PSA values > 20 ng/ml, ISUP grade > 3 and MRI T-stage > 3, according to research presented recently at the SNMMI conference.
